MAPK-IN-1
Based on 4 publication(s) in Google Scholar
MAPK-IN-1 (Compound 2) is a MAPK signaling pathway inhibitor. MAPK-IN-1 exhibits AChE inhibitory activity with an IC50 of 23.84 μM. MAPK-IN-1 shows anti-neuroinflammatory and neuroprotective activity and can be used for Alzheimer's disease research.
For research use only. We do not sell to patients.
- Purity: 98.11%
- CAS No.: 2470587-69-8
- Formula: C19H18O4
- Molecular Weight:310.34
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) MAPK-IN-1
More
Biological Activity
|
TLR4 |
MAPK-IN-1 (Compound 2) inhibits NO, IL-1β, IL-6, and TNF-α release in BV-2 cells with IC50 values of 0.49 ± 0.17, 1.34 ± 0.21, 9.17 ± 0.17 and 8.17 ± 0.23 μM, respectively[1].
MAPK-IN-1 downregulates LPS-induced phosphorylation of JNK, ERK, and p38 in MAPK signaling pathway[1].
MAPK-IN-1 inhibits expressions of iNOS, COX-2, and TLR4 in LPS-induced BV-2 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2470587-69-8
-
Appearance Solid
-
Molecular Weight 310.34
-
Formula C19H18O4
-
Color Orange to red
-
SMILES
O=C1CCC(C2=C(C3=C(C(C2=O)=O)[C@@H](C)CO3)C=C4)=C4C1(C)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Biochem Pharmacol
Blocking the LRH-1/LCN2 axis by ML-180, an LRH-1 inverse agonist, ameliorates osteoarthritis via inhibiting the MAPK pathway. [Abstract]2025 Apr 5:116922. PMID: 40194607 -
Int Immunopharmacol
CORM-3 mitigates osteoarthritis by anti-inflammation and enhancing autophagy via inhibiting MAPK and mTOR pathways. [Abstract]2025 Jul 31:163:115296. PMID: 40749610 -
Anal Cell Pathol
m6A-Mediated Stabilization of PRMT9 mRNA by IGF2BP1 Drives Proliferation and Metastasis in Lung Adenocarcinoma. [Abstract]2025 Dec 10:2025:6050688. PMID: 41394407 -
Adv Biol (Weinh)
2024 Jul 2:e2300517. PMID: 38955672
Solvent & Solubility
DMSO : 100 mg/mL (322.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.06 mM); Suspended solution
This protocol yields a suspended solution of ≥ 2.5 mg/mL (saturation unknown). Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.06 mM); Suspended solution
This protocol yields a suspended solution of ≥ 2.5 mg/mL (saturation unknown). Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2223 mL | 16.1114 mL | 32.2227 mL | 80.5568 mL |
| 5 mM | 0.6445 mL | 3.2223 mL | 6.4445 mL | 16.1114 mL | |
| 10 mM | 0.3222 mL | 1.6111 mL | 3.2223 mL | 8.0557 mL | |
| 15 mM | 0.2148 mL | 1.0741 mL | 2.1482 mL | 5.3705 mL | |
| 20 mM | 0.1611 mL | 0.8056 mL | 1.6111 mL | 4.0278 mL | |
| 25 mM | 0.1289 mL | 0.6445 mL | 1.2889 mL | 3.2223 mL | |
| 30 mM | 0.1074 mL | 0.5370 mL | 1.0741 mL | 2.6852 mL | |
| 40 mM | 0.0806 mL | 0.4028 mL | 0.8056 mL | 2.0139 mL | |
| 50 mM | 0.0644 mL | 0.3222 mL | 0.6445 mL | 1.6111 mL | |
| 60 mM | 0.0537 mL | 0.2685 mL | 0.5370 mL | 1.3426 mL | |
| 80 mM | 0.0403 mL | 0.2014 mL | 0.4028 mL | 1.0070 mL | |
| 100 mM | 0.0322 mL | 0.1611 mL | 0.3222 mL | 0.8056 mL |
Powered by Bioz